The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...

Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & Johnson is confident it can eke out revenue growth this year despite the ...

Q4 2024 Management View CEO David Cordani highlighted Cigna's full-year revenue growth of $247 billion, a 27% increase, alongside adjusted EPS of $27.33, which fell short of expectations. He ...

Shares of Formycon AG (ETR:FYB) tumbled 39.16% on Monday following the company's announcement regarding the termination of ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving the way for its US launch. Celltrion’s Stelara biosimilar ustekinumab ...

Likely," according to Drug Channels. The PBMs are also featuring Stelara biosimilars, branded by private labels affiliated with their patient companies, this year.

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced ...

In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA ...